CPC 551

Drug Profile

CPC 551

Alternative Names: CPC551; OT-551

Latest Information Update: 10 Jun 2015

Price : $50

At a glance

  • Originator Othera Pharmaceuticals
  • Class Cyclopropanes; Eye disorder therapies; Hydroxylamines; Piperidines; Small molecules
  • Mechanism of Action Antioxidants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry macular degeneration
  • Discontinued Cataracts; Dry eyes

Most Recent Events

  • 10 Jun 2015 Clinical development is ongoing for age-related macular degeneration in USA
  • 13 Dec 2012 Colby Pharmaceuticals will continue the development of OT 551
  • 19 Sep 2012 Colby Pharmaceuticals acquires Othera Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top